Firms to investigate RNAi for Huntington's disease

12/27/2010 | Wall Street Journal, The

Alnylam Pharmaceuticals and Medtronic have teamed up to develop a treatment for Huntington's disease using RNA interference, which can focus on a gene responsible for the production of disease-causing proteins. Medtronic will develop a catheter or a pump that can deliver Alnylam's short, interfering RNA drug directly to the correct area of the brain.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA